menu
    • menu
    [{"orgOrder":0,"company":"AriBio","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"CREB pathway","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ SK Chemicals","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ SK Chemicals"},{"orgOrder":0,"company":"AriBio","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"PDE5","graph1":"Neurology","graph2":"Phase II","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Cleveland Clinic Genomic Medicine Institute","highestDevelopmentStatusID":"8","companyTruncated":"AriBio \/ Cleveland Clinic Genomic Medicine Institute"},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Not Applicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Not Applicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Mirodenafil","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0.77000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.77000000000000002,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Undisclosed"},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mirodenafil dihydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Not Applicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirodenafil dihydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Not Applicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Not Applicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Not Applicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Adaptive Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AriBio \/ Adaptive Research","highestDevelopmentStatusID":"14","companyTruncated":"AriBio \/ Adaptive Research"}]

    Find Clinical Drug Pipeline Developments & Deals by AriBio

    Menu

    AriBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Adaptive Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Adaptive Research Enrolls Patients in AriBio’s Phase 3 POLARIS-AD Trial

                            Details : AR1001 is a phosphodiesterase-5 (PDE5) inhibitor being developed as an oral agent for the treatment of early Alzheimer’s disease.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 30, 2024

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Adaptive Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AriBio gets IND approval for Phase 3 Alzheimer’s trial in China

                            Details : AR1001 is a phosphodiesterase-5 (PDE5) inhibitor being developed as an investigational oral agent being investigated for the treatment of early Alzheimer’s disease.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 14, 2024

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AriBio Receives EMA Phase 3 Trial Authorization for AR1001 in Alzheimer’s Disease

                            Details : AR1001 is a phosphodiesterase-5 (PDE5) inhibitor being developed as an investigational oral agent being investigated for the treatment of early Alzheimer’s disease.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 28, 2024

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirodenafil

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $770.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China

                            Details : AriBio has concluded an exclusive distribution agreement with a Chinese pharmaceutical company for AR1001 (mirodenafil), an oral PDE5 inhibitor, for the treatment for Alzheimer's disease, in China.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : $90.0 million

                            March 24, 2024

                            Lead Product(s) : Mirodenafil

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $770.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirodenafil dihydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MHRA Accepts POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial by AriBio Co., Ltd

                            Details : AR1001 (mirodenafil dihydrochloride) is an oral PDE5 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of patients with Alzheimer's Disease.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 25, 2024

                            Lead Product(s) : Mirodenafil dihydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirodenafil dihydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AriBio Co., Ltd. Announces Global Expansion of POLARIS-AD, A Phase 3 Early Alzheimer’s Disease Registration ...

                            Details : AR1001 is an oral PDE5 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of patients with Alzheimer's Disease.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 14, 2023

                            Lead Product(s) : Mirodenafil dihydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Participants Enrolled in the AriBio USA Phase 3 Registration Trial to Evaluate AR1001 in Early Alzheimer...

                            Details : AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2023

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AriBio Co., Ltd. Announces the Successful Completion of Their End of Phase 2 Meeting With the USFDA

                            Details : Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity, also has demonstrated notable effects against amyloid plaques and tau proteins via autophagy activation.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 04, 2022

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Cleveland Clinic

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Dis...

                            Details : Positive Phase II trial reported for AR1001, the results confirmed the possibility of developing a unique oral disease-modifying treatment for AD that improves cognitive function. The Company will complete Phase III clinical trials of AR1001 within the n...

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2021

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Cleveland Clinic

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            AriBio

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : SK Chemicals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001

                            Details : AriBio completed enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease.

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 17, 2020

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : SK Chemicals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth